Understanding the Market | 3SBIO rises over 8% as SSGJ707 Phase II data is excellent; institutions indicate its innovative drugs are entering the harvest period
I'm PortAI, I can summarize articles.
3SBIO's stock price rose by more than 8%, with an increase of 8.22% as of the time of publication, trading at HKD 9.22, with a turnover of HKD 399 million. The company disclosed excellent Phase II clinical data for SSGJ707 at the JP Morgan conference, showing good anti-tumor activity and safety, especially in patients with non-small cell lung cancer and metastatic colorectal cancer. Soochow Securities expects that the domestic sales peak of SSGJ707 could reach 4 billion yuan, while the overseas sales peak could reach 4.5 billion USD, and the company has strong cash assets to support the research and development of innovative drugs
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments